CN114522148B - Compound caraway enteric liquid capsule and preparation method and application thereof - Google Patents
Compound caraway enteric liquid capsule and preparation method and application thereof Download PDFInfo
- Publication number
- CN114522148B CN114522148B CN202210151969.3A CN202210151969A CN114522148B CN 114522148 B CN114522148 B CN 114522148B CN 202210151969 A CN202210151969 A CN 202210151969A CN 114522148 B CN114522148 B CN 114522148B
- Authority
- CN
- China
- Prior art keywords
- capsule
- compound
- oil
- caraway
- enteric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 79
- 240000000467 Carum carvi Species 0.000 title claims abstract description 72
- 235000005747 Carum carvi Nutrition 0.000 title claims abstract description 72
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 title claims abstract description 49
- 239000007788 liquid Substances 0.000 title claims abstract description 48
- 150000001875 compounds Chemical class 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 239000003921 oil Substances 0.000 claims abstract description 29
- 235000019198 oils Nutrition 0.000 claims abstract description 29
- 239000001525 mentha piperita l. herb oil Substances 0.000 claims abstract description 19
- 235000019477 peppermint oil Nutrition 0.000 claims abstract description 19
- 239000010642 eucalyptus oil Substances 0.000 claims abstract description 18
- 229940044949 eucalyptus oil Drugs 0.000 claims abstract description 18
- 238000011049 filling Methods 0.000 claims abstract description 17
- 239000007902 hard capsule Substances 0.000 claims abstract description 17
- 239000003566 sealing material Substances 0.000 claims abstract description 15
- 229920001213 Polysorbate 20 Polymers 0.000 claims abstract description 13
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims abstract description 13
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims abstract description 13
- 239000011248 coating agent Substances 0.000 claims abstract description 10
- 238000000576 coating method Methods 0.000 claims abstract description 10
- 238000002156 mixing Methods 0.000 claims abstract description 10
- 241000949456 Zanthoxylum Species 0.000 claims abstract description 6
- 238000005303 weighing Methods 0.000 claims abstract description 5
- 229920000136 polysorbate Polymers 0.000 claims abstract description 3
- 239000002994 raw material Substances 0.000 claims abstract description 3
- 239000000341 volatile oil Substances 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 13
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 10
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 10
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 10
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 10
- 201000006549 dyspepsia Diseases 0.000 claims description 9
- 230000008014 freezing Effects 0.000 claims description 9
- 238000007710 freezing Methods 0.000 claims description 9
- 238000000874 microwave-assisted extraction Methods 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000007903 gelatin capsule Substances 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 5
- 239000004925 Acrylic resin Substances 0.000 claims description 3
- 229920000178 Acrylic resin Polymers 0.000 claims description 3
- 239000001856 Ethyl cellulose Substances 0.000 claims description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 2
- ULDHMXUKGWMISQ-UHFFFAOYSA-N carvone Chemical compound CC(=C)C1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-UHFFFAOYSA-N 0.000 description 22
- 238000000605 extraction Methods 0.000 description 12
- 239000005973 Carvone Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- 239000010643 fennel seed oil Substances 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 6
- 238000004817 gas chromatography Methods 0.000 description 5
- 238000007873 sieving Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 241000722731 Carex Species 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- -1 sucrose fatty acid Chemical class 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 206010059186 Early satiety Diseases 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000019525 fullness Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229920003087 methylethyl cellulose Polymers 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 239000002325 prokinetic agent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a compound Carum carvi enteric liquid capsule and a preparation method and application thereof, belonging to the technical field of pharmaceutical preparations; the compound caraway enteric liquid capsule consists of a hard capsule shell, contents and a sealing material; the content comprises the following raw materials in parts by weight: 40 to 50 portions of zanthoxylum oil, 80 to 90 portions of peppermint oil, 20 to 3 portions of tween and 10 to 20 portions of eucalyptus oil; weighing the caraway extract, the peppermint oil, the tween 20 and the eucalyptus oil according to the weight parts, mixing, filling into the hard capsule shell, sleeving, and coating a sealing material at the sleeving part to obtain the compound caraway enteric liquid capsule; when the compound caraway enteric liquid capsule prepared by the invention is stored in a high-temperature environment, the embrittlement degree of the capsule shell is remarkably relieved, so that the overall high-temperature resistance of the capsule is improved, and the disintegration time of the capsule is basically kept unchanged after the capsule is stored for 30 days at 40 ℃.
Description
Technical Field
The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a compound caraway enteric liquid capsule, and a preparation method and application thereof.
Background
Functional dyspepsia is one of functional gastroenteropathy, refers to one or a group of symptoms originating from stomach and duodenum regions, and no organic pathological changes are researched for the functional dyspepsia symptoms at present. Functional dyspepsia is a common clinical condition, and the main clinical symptoms are postprandial fullness, early satiety, epigastric pain or burning sensation of the upper abdomen, which has the characteristics of chronic, persistent or repeated attack and seriously affects the life quality of patients. At present, acid inhibitors, prokinetic agents, gastric mucosa protective agents and the like are frequently adopted for treating functional dyspepsia. In recent years, compound capsules prepared by compounding caraway oil and peppermint oil are widely concerned as medicines for treating functional dyspepsia. The Tibetan fennel oil is colorless or light yellow clear liquid, and the existing research shows that the Tibetan fennel oil mainly contains carvone, limonene and the like, has unique fragrance, and has good treatment effect on the symptoms of epigastric pain, abdominal pain, dyspepsia, intestinal hernia and the like. The oleum Menthae Dementholatum is volatile oil extracted from herba Menthae, and has colorless or light yellow clear liquid appearance, and the oleum Menthae Dementholatum contains Mentholum, and has certain therapeutic effect on regurgitation, gastrointestinal spasm and flatulence.
The Tibetan fennel oil and the peppermint oil are combined, so that the capsule has a good treatment effect on functional dyspepsia, but the Tibetan fennel oil and the peppermint oil belong to volatile oils, so that the capsule is usually prepared, the low-temperature storage performance of the hard capsule prepared from the Tibetan fennel oil and the peppermint oil is good, but at a high temperature (40 ℃), the hard capsule shell is deformed and deteriorated, the disintegration time limit of the capsule is prolonged, the quality of the capsule is seriously influenced, and the exertion of the medicine effect of the capsule is influenced.
Disclosure of Invention
The invention provides a compound caraway enteric liquid capsule, a preparation method and application thereof aiming at the defects in the prior art.
In order to achieve the purpose, the invention provides the following technical scheme:
the invention provides a compound caraway enteric liquid capsule, which consists of a hard capsule shell, contents and a sealing material; the content comprises the following raw materials in parts by weight: 40 to 50 portions of zanthoxylum oil, 80 to 90 portions of peppermint oil, 20 to 3 portions of tween and 10 to 20 portions of eucalyptus oil.
Further, the preparation method of the zanthoxylum oil comprises the following steps: freezing Carum carvi, adding water, microwave extracting, and collecting volatile oil to obtain Carum carvi oil.
Further, the freezing temperature is-10 to-20 ℃, and the time is 48 to 72 hours; the water adding amount is 5-8 times of the mass of the Carum carvi.
Furthermore, the microwave extraction voltage is 150-180V, and the time is 4-5 h.
When volatile oil of the caraway is extracted, the extraction rate of the volatile oil in the caraway is higher and can reach 99.1 percent to the maximum by adopting a method of firstly freezing and then extracting by microwave, thereby obviously improving the utilization rate of the caraway.
Further, the hard capsule shell is an enteric capsule shell made of a gelatin capsule shell, a starch capsule shell or a hydroxypropyl methylcellulose capsule shell.
Further, the sealing material is hydroxypropyl methyl cellulose, ethyl cellulose or acrylic resin.
The invention also provides a preparation method of the compound fructus Cari enteric liquid capsule, which comprises the following steps: weighing the caraway extract, the peppermint oil, the tween 20 and the eucalyptus oil according to the weight parts, mixing, filling into the hard capsule shell, sleeving, and coating a sealing material at the sleeving part to obtain the compound caraway enteric liquid capsule.
The invention also provides application of the compound fructus Cari enteric liquid capsule in preparing a medicament for treating functional dyspepsia.
Compared with the prior art, the invention has the following beneficial effects:
according to the invention, the caraway oil and the mint oil are compounded, and the tween 20 and the eucalyptus oil are added as capsule contents, so that the disintegration time of the prepared compound caraway enteric liquid capsule is stable, and the brittle deformation degree of a capsule shell is remarkably relieved when the capsule is stored at a high temperature environment, so that the integral high temperature resistance of the capsule is improved, and the disintegration time of the capsule is basically kept unchanged after the capsule is stored at 40 ℃ for 30 days.
Detailed Description
Reference will now be made in detail to various exemplary embodiments of the invention, the detailed description should not be construed as limiting the invention but rather as a more detailed description of certain aspects, features and embodiments of the invention. It is to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention.
In addition, for numerical ranges in the present disclosure, it is understood that each intervening value, to the upper and lower limit of that range, is also specifically disclosed. Every smaller range between any stated value or intervening value in a stated range and any other stated or intervening value in a stated range is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included or excluded in the range.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although only preferred methods and materials are described herein, any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention. All documents mentioned in this specification are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the documents are cited. In case of conflict with any incorporated document, the present specification will control.
It will be apparent to those skilled in the art that various modifications and variations can be made in the specific embodiments of the present disclosure without departing from the scope or spirit of the disclosure. Other embodiments will be apparent to those skilled in the art from consideration of the specification. The description and examples are intended to be illustrative only.
As used herein, the terms "comprising," "including," "having," "containing," and the like are open-ended terms that mean including, but not limited to.
The "parts" in the present invention are in parts by weight unless otherwise specified.
In the following examples, the peppermint oil and the eucalyptus oil are commercially available, the menthol content in the peppermint oil is 30%, the eucalyptol content in the eucalyptus oil is 82%, and the caraway is caraway produced by Tibet, and the description thereof will not be repeated.
Example 1
The preparation method of the compound fructus Cari enteric liquid capsule comprises the following steps:
(1) Preparing Tibetan fennel oil: taking 100g of dried caraway, crushing, sieving by a 14-mesh sieve, freezing at-15 ℃ for 60 hours, taking out, adding 6.5 times of water by mass, extracting by a microwave extraction method at 160V for 4.5 hours, and collecting 8.0mL of volatile oil to obtain caraway oil;
the content of carvone in 100g of dried Carum carvi is 4.28g, and the extraction rate of volatile oil in Carum carvi is calculated by taking the data as 100%; detecting the content of carvone in the obtained Carex Carvi oil by gas chromatography, wherein the obtained result is 4.12g, and the extraction rate of volatile oil is 96.3%;
(2) And (2) taking 45 parts of the caraway oil obtained in the step (1), 85 parts of peppermint oil, 2 parts of tween 20 and 15 parts of eucalyptus oil, uniformly mixing, filling the mixture into an enteric capsule shell made of a No. 2 gelatin capsule shell by using a liquid hard capsule filling machine, sleeving the mixture, and coating an annular hydroxypropyl methyl cellulose sealing material at the sleeving part to obtain the compound caraway enteric liquid capsule.
Example 2
The preparation method of the compound fructus Cari enteric liquid capsule comprises the following steps:
(1) Preparing Tibetan fennel oil: taking 100g of dried caraway, crushing, sieving with a 10-mesh sieve, freezing at-10 ℃ for 72h, taking out, adding 8 times of water by mass, extracting for 4h by adopting a microwave extraction method at a voltage of 180V, and collecting 7.5mL of volatile oil to obtain caraway oil;
the content of carvone in 100g of dried Carum carvi is 4.28g, and the extraction rate of volatile oil in Carum carvi is calculated by taking the data as 100%; detecting content of carvone in the obtained Carum carvi oil by adopting gas chromatography, wherein the obtained result is 4.07g, and the extraction rate of volatile oil is 95.1%;
(2) And (2) taking 40 parts of the caraway oil obtained in the step (1), 80 parts of peppermint oil, 1 part of tween 20 and 10 parts of eucalyptus oil, uniformly mixing, filling the mixture into an enteric capsule shell made of a No. 2 starch capsule shell by using a liquid hard capsule filling machine, sleeving the enteric capsule shell, and coating an annular ethyl cellulose sealing material at the sleeving position to obtain the compound caraway enteric liquid capsule.
Example 3
The preparation method of the compound fructus Cari enteric liquid capsule comprises the following steps:
(1) Preparing Tibetan fennel oil: taking 100g of dried caraway, crushing, sieving by a 20-mesh sieve, freezing at-20 ℃ for 48 hours, taking out, adding 5 times of water by mass, extracting for 5 hours by a microwave extraction method at a voltage of 150V, and collecting 7.7mL of volatile oil to obtain caraway oil;
the content of carvone in 100g dried fructus Cari Carvi is 4.28g, and the extraction rate of volatile oil in fructus Cari Carvi is calculated by taking the data as 100%; detecting the content of carvone in the obtained Carex carvi oil by adopting a gas chromatography, wherein the obtained result is 4.09g, and the extraction rate of volatile oil is 95.6%;
(2) Taking 50 parts of the caraway oil obtained in the step (1), 90 parts of peppermint oil, 3 parts of tween 20 and 20 parts of eucalyptus oil, uniformly mixing, filling the mixture into an enteric capsule shell prepared from a No. 2 hydroxypropyl methylcellulose capsule shell by using a liquid hard capsule filling machine, sleeving the enteric capsule shell, and then coating an annular acrylic resin sealing material at the sleeving part to obtain the compound caraway enteric liquid capsule.
Example 4
The preparation method of the compound Carum carvi enteric liquid capsule comprises the following steps:
(1) Preparing the zanthoxylum oil: taking 100g of dried caraway, crushing, sieving with a 14-mesh sieve, freezing at-15 ℃ for 60h, taking out, adding 6.5 times of water by mass, simultaneously adding 1.5g of sucrose fatty acid monoester, extracting for 4.5h by adopting a microwave extraction method at a voltage of 160V, and collecting 8.3mL of volatile oil to obtain caraway oil;
the content of carvone in 100g of dried Carum carvi is 4.28g, and the extraction rate of volatile oil in Carum carvi is calculated by taking the data as 100%; detecting content of carvone in the obtained Carum carvi oil by adopting gas chromatography, wherein the obtained result is 4.23g, and the extraction rate of volatile oil is 98.8%; therefore, when the volatile oil in the caraway is subjected to microwave extraction, a certain amount of sucrose fatty acid monoester is added, so that the extraction rate of the volatile oil can be improved.
(2) And (2) taking 45 parts of the caraway oil obtained in the step (1), 85 parts of peppermint oil, 2 parts of tween 20 and 15 parts of eucalyptus oil, uniformly mixing, filling the mixture into an enteric capsule shell made of a No. 2 gelatin capsule shell by using a liquid hard capsule filling machine, sleeving the mixture, and coating an annular hydroxypropyl methyl cellulose sealing material at the sleeving part to obtain the compound caraway enteric liquid capsule.
Comparative example 1
The preparation method of the compound Carum carvi enteric liquid capsule comprises the following steps:
(1) Preparing the zanthoxylum oil: taking 100g of dried caraway, crushing, sieving with a 14-mesh sieve, adding 6.5 times of water by mass, extracting for 4.5h by adopting a microwave extraction method at a voltage of 160V, and collecting 6.9mL of volatile oil to obtain caraway oil;
the content of carvone in 100g dried fructus Cari Carvi is 4.28g, and the extraction rate of volatile oil in fructus Cari Carvi is calculated by taking the data as 100%; detecting the content of carvone in the obtained Carex Carvi oil by gas chromatography, wherein the obtained result is 3.89g, and the extraction rate of volatile oil is 90.9%;
(2) And (2) taking 45 parts of the caraway oil obtained in the step (1), 85 parts of peppermint oil, 2 parts of tween 20 and 15 parts of eucalyptus oil, uniformly mixing, filling the mixture into an enteric capsule shell made of a No. 2 gelatin capsule shell by using a liquid hard capsule filling machine, sleeving the mixture, and coating an annular hydroxypropyl methyl cellulose sealing material at the sleeving part to obtain the compound caraway enteric liquid capsule.
Comparative example 2
The preparation method of the compound Carum carvi enteric liquid capsule comprises the following steps:
the step (1) is the same as the example 1, and the step (2) is as follows: and (2) uniformly mixing 45 parts of the Carum carvi oil obtained in the step (1), 85 parts of peppermint oil and 2 parts of Tween 20, filling the mixture into an enteric capsule shell made of a No. 2 gelatin capsule shell by using a liquid hard capsule filling machine, sleeving the enteric capsule shell, and coating an annular hydroxypropyl methylcellulose sealing material at the sleeving part to obtain the compound Carum carvi enteric liquid capsule.
Comparative example 3
The preparation method of the compound Carum carvi enteric liquid capsule comprises the following steps:
the step (1) is the same as the example 1, and the step (2) is: and (2) taking 45 parts of the caraway oil obtained in the step (1), 85 parts of peppermint oil and 15 parts of eucalyptus oil, uniformly mixing, filling the mixture into an enteric capsule shell made of a No. 2 gelatin capsule shell by using a liquid hard capsule filling machine, sleeving the enteric capsule shell, and then coating an annular hydroxypropyl methyl cellulose sealing material at the sleeving part to obtain the compound caraway enteric liquid capsule.
Effect verification
1. According to the stability test of the medicine in the appendix of the Chinese pharmacopoeia 2020 edition, the inspection method and the limit requirement under the capsule item, the disintegration time limit of the compound caraway enteric liquid capsule prepared in the embodiments 1 to 4 and the comparative examples 1 to 3 is detected and is recorded as 0 day disintegration time; then respectively placing 30 pieces of the compound caraway enteric liquid capsules prepared in the embodiments 1-4 and the comparative examples 1-3 in an open weighing bottle, storing for 24 months at 25 ℃, and detecting the disintegration time limit according to the method; 30 capsules of compound fructus Cari enteric liquid prepared in examples 1-4 and comparative examples 1-3 were placed in open weighing bottles, respectively, and placed in an environment of 40 ℃ for 30 days, and the disintegration time was measured according to the above method, and the results are shown in table 1:
TABLE 1
As can be seen from table 1: when the capsule contains the Tween 20 and the eucalyptus oil, the normal-temperature storage performance and the high-temperature resistance of the capsule are higher than those of the capsule containing only the Tween 20 or only the eucalyptus oil, which shows that the Tween 20 and the eucalyptus oil are beneficial to improving the normal-temperature stability and the high-temperature resistance of the capsule.
The above description is only for the preferred embodiment of the present invention, and the protection scope of the present invention is not limited thereto, and any person skilled in the art should be able to cover the technical scope of the present invention, the technical solution and the inventive concept of the present invention equivalent or change within the technical scope of the present invention.
Claims (8)
1. A compound fructus Cari enteric liquid capsule is characterized by comprising a hard capsule shell, contents and a sealing material; the content comprises the following raw materials in parts by weight: 40 to 50 portions of zanthoxylum oil, 80 to 90 portions of peppermint oil, 20 to 3 portions of tween and 10 to 20 portions of eucalyptus oil.
2. The enteric compound caraway liquid capsule of claim 1, wherein the preparation method of caraway oil comprises: freezing Carum carvi, adding water, performing microwave extraction, and collecting volatile oil to obtain Carum carvi oil.
3. The compound Carum carvi enteric liquid capsule according to claim 2, wherein the freezing temperature is-10 to-20 ℃ and the time is 48 to 72 hours; the water adding amount is 5-8 times of the mass of the Carum carvi.
4. The compound fructus Cari Carvi enteric liquid capsule of claim 2, wherein the microwave extraction voltage is 150-180V and the time is 4-5 h.
5. The compound Carum carvi enteric liquid capsule according to claim 1, wherein the hard capsule shell is an enteric capsule shell made of gelatin capsule shell, starch capsule shell or hydroxypropyl methylcellulose capsule shell.
6. The compound fructus Cari enteric liquid capsule of claim 1, wherein the sealing material is hydroxypropylmethyl cellulose, ethyl cellulose or acrylic resin.
7. A method for preparing the compound caraway enteric liquid capsule as claimed in any one of claims 1 to 6, characterized by comprising the following steps: weighing the caraway extract, the peppermint oil, the tween 20 and the eucalyptus oil according to the weight parts, mixing, filling into the hard capsule shell, sleeving, and coating a sealing material at the sleeving part to obtain the compound caraway enteric-coated liquid capsule.
8. The use of the compound fructus Cari enteric liquid capsule of any one of claims 1-6 in the preparation of a medicament for treating functional dyspepsia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210151969.3A CN114522148B (en) | 2022-02-18 | 2022-02-18 | Compound caraway enteric liquid capsule and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210151969.3A CN114522148B (en) | 2022-02-18 | 2022-02-18 | Compound caraway enteric liquid capsule and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114522148A CN114522148A (en) | 2022-05-24 |
| CN114522148B true CN114522148B (en) | 2023-03-10 |
Family
ID=81623449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210151969.3A Active CN114522148B (en) | 2022-02-18 | 2022-02-18 | Compound caraway enteric liquid capsule and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114522148B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1887310A (en) * | 2005-06-30 | 2007-01-03 | 天津药物研究院 | Compound fennel capsule for treating indigestion and its prepn process |
| CN106344536A (en) * | 2016-01-12 | 2017-01-25 | 河北爱尔海泰制药有限公司 | Caraway-containing compound capsule composition and preparation method thereof |
-
2022
- 2022-02-18 CN CN202210151969.3A patent/CN114522148B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1887310A (en) * | 2005-06-30 | 2007-01-03 | 天津药物研究院 | Compound fennel capsule for treating indigestion and its prepn process |
| CN106344536A (en) * | 2016-01-12 | 2017-01-25 | 河北爱尔海泰制药有限公司 | Caraway-containing compound capsule composition and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114522148A (en) | 2022-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101396381B (en) | Valerian extract and preparation method and use thereof | |
| CN102438630A (en) | Pharmaceutical composition for treating depression and preparative method and use thereof | |
| US8361515B2 (en) | Extracts of Chenopodium ambrosioides L., the compositions comprising said extracts, the preparing process and application thereof | |
| WO2022022020A1 (en) | Traditional chinese medicine composition, preparation method and use | |
| CN114522148B (en) | Compound caraway enteric liquid capsule and preparation method and application thereof | |
| CN103800352B (en) | Compound traditional Chinese medicinal effective component preparation for resisting alcoholic fatty liver disease and application thereof | |
| CN101007044B (en) | A medicine composition for treating peptic ulcer, preparing method and use thereof | |
| WO2018223625A1 (en) | Pharmaceutical composition and use thereof | |
| CN114699436B (en) | Application of traditional Chinese medicine extract composition for preventing and treating influenza in preparation of medicines for inhibiting death caused by influenza virus and inhibiting lung injury caused by influenza virus | |
| CN103191167B (en) | Application of eupatorium Chinese | |
| CN102688263B (en) | Geranium strictipes effective part preparation and medical use of geranium strictipes for preventing and curing colonitis | |
| CN109939100B (en) | Acetylcholine enzyme inhibitor prepared from Cyrtomium fortunei, preparation method and application | |
| Qi et al. | Genetic analysis of the VP2 hypervariable region of thirty-six infectious bursal disease virus isolates in China during 2009-2012 | |
| CN107854656A (en) | A kind of Chinese traditional medicines depressing lipid composition and its production and use | |
| CN103977300B (en) | One has the pancreatitic Traditional Chinese medicine compound composition for the treatment of and application thereof | |
| CN109939200B (en) | Traditional Chinese medicine composition and application thereof in preparation of medicine for treating acute kidney injury | |
| CN101947290A (en) | Medicament with yin-nourishing effect | |
| CN102048860B (en) | A kind of soft capsule for nasosinusitis pharmaceutical preparation and preparation method thereof | |
| CN104042607B (en) | For pharmaceutical composition treating dementia and preparation method thereof | |
| CN115463164B (en) | Preparation method of ephedra root ethyl acetate part, and medicine and application thereof | |
| CN100423737C (en) | Liquor for improving function of human immunity | |
| CN106822071A (en) | It is a kind of for treating coronary heart disease, the effective ingredient in Chinese of hyperlipidemia, preparation method and the therefrom method of separating effective ingredient | |
| CN103417605A (en) | Preparation method and application of drug or health product for treatment of liver injury | |
| CN109908120B (en) | Effective component of Dryopteris stenoptera, extraction method and application thereof | |
| CN112402505B (en) | Traditional Chinese medicine composition and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |